tirzepatide patient information for Medical Weight Loss Tirzepatide Dosing Chart: Weekly Guide

FDA approves Novo Nordisks oral semaglutide (Rybelsus) for CV risk reduction in T2DM adults owenhaskins Oct 20, 2025 3 min read Novo Nordisk has received FDA approval for Rybelsus for reducing the risk of major adverse cardiovascular events (MACE) such as cardiovascular (CV) death, heart attack, or stroke in adults with type 2 diabetes who are at high risk for these events, whether they've had a prior CV event or not (primary and secondary prevention)

It also does not treat type 1 diabetes, where the body makes little or no insulin

The new weight-loss drugs have created a hope and optimism among my patients that I have frankly not seen before, says Sarah C

MRC Weight Loss Coaches will be there for you every step of the way

LAURA: So, last time I injected into the skin on my thigh, but you need to rotate where you inject each time

Ultimately, this could help develop safer and more individualized dietary interventions